Atopic Dermatitis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the atopic dermatitis market size is projected to be USD 19.38 billion in 2025, USD 21.15 billion in 2026, and reach USD 33.29 billion by 2031, growing at a CAGR of 9.5% from 2026 to 2031.

This report is Segmented by Drug Class (Corticosteroids, and More), Route of Administration (Topical, Oral, and Injectable), Patient Age Group (Pediatric 0-17 Yrs and Adult 18+ Yrs), Distribution Channel (Hospital, Retail, and Online/Tele-Dermatology), and Geography (North America, Europe, Asia-Pacific, MEA, and South America). Market Forecasts are Provided in Value (USD).

Global Atopic Dermatitis Market Trends and Insights

Rising Global Disease Burden Across Pediatric and Adult Populations

Prevalence climbed to 15-20% among children and 7-10% among adults in industrialized nations by 2025, while emerging economies recorded a faster incidence linked to urbanization and diminished early-life microbial exposure. The expanding patient pool sustains demand for both maintenance therapy and flare management, which reduces exposure to economic cycles. Pediatric onset frequently persists into adulthood, creating lifetime treatment trajectories that raise switching costs once a biologic achieves control. The Asia-Pacific region shows the steepest incidence curve, likely tied to rapid urban migration and air quality degradation. Payers are moving from reactive rescue therapy toward proactive maintenance, favoring long-acting injectables. The demographic tailwind therefore supports both volume and price growth through 2031.

Accelerated Regulatory Approvals of First-In-Class Biologics And JAK Inhibitors

Regulators issued eight key approvals or label expansions between January 2024 and September 2025, tripling the pace of the prior five-year period. The FDA cleared lebrikizumab in September 2024 for the treatment of adults with moderate to severe disease. AbbVie gained U.S. adolescent labeling for upadacitinib in May 2024, enlarging its eligible population by over one million patients. Japan's PMDA approved abrocitinib for pediatrics in March 2024, confirming JAK1 selectivity as appropriate for younger cohorts. Harmonized review procedures across FDA, EMA, and PMDA shortened global rollout timelines and reduced late-stage capital intensity, which encourages smaller biotechs to push novel mechanisms into Phase III.

High Annual Therapy Costs Limiting Patient Access to Novel Systemic Agents

Wholesale acquisition costs exceeded USD 40,000 for dupilumab and USD 35,000-38,000 for upadacitinib and abrocitinib in the United States during 2025. Assistance programs lower costs for commercial plans but exclude Medicare beneficiaries under anti-kickback rules, leaving gaps for older adults. In India, biosimilar dupilumab priced at USD 12,000 still represents several times the median income, limiting uptake to urban elites. Step-therapy mandates impose 6-12 month delays and may worsen disease. Cold-chain logistics further inflate injectable prices. Biosimilars after 2028 are expected to compress costs, but exclusivity for newer biologics will persist until 2030.

Other drivers and restraints analyzed in the detailed report include:

1. Expansion of Universal Healthcare and Private Insurance Coverage in Emerging Markets
2. AI-Enabled Decision Support Improving Early Diagnosis And Personalized Treatment
3. Ongoing Safety and Label Restriction Concerns for JAK Inhibitors

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Corticosteroids retained 34.8% of the revenue in 2025, yet IL-4, IL-13, and JAK inhibitors are forecast to grow at 11.2% annually through 2031, nearly double the broader atopic dermatitis market's CAGR. Dupilumab alone generated USD 11.6 billion in sales in 2024, of which roughly 60% came from atopic dermatitis. The atopic dermatitis market size for biologics is projected to expand sharply once pediatric and emerging-market coverage deepen. Calcineurin inhibitors and PDE4 topicals occupy mid-tier positions, but newer options, such as ruxolitinib cream, are gaining traction due to their faster itch relief. Patent expiries between 2028 and 2029 will open the space for biosimilars; however, complex antibody manufacturing will limit the field to a handful of entrants.

Broader prescribing authority is sliding toward dermatologists, with allergists and primary-care doctors referring sooner for biologic evaluation. Eli Lilly's lebrikizumab differs in its monthly dosing regimen after the loading phase, addressing adherence fatigue associated with every-other-week regimens and potentially capturing a larger share of the atopic dermatitis market. Emollients remain foundational but low-revenue. Stewardship programs constrain antibiotic use. Collectively, biologics and JAK inhibitors reshape revenue distribution in the atopic dermatitis market.

Topicals accounted for 61.2% of revenue in 2025, yet real-world adherence falls below 50% beyond three months. Injectables are expanding at a rate of 10.5% annually, driven by monthly or bi-weekly biologics that reduce the dosing burden. The atopic dermatitis market size for injectables is expected to grow as biosimilar entry after 2028 reduces cost barriers. Oral JAK inhibitors offer once-daily convenience but face boxed-warning resistance. Arcutis's once-daily roflumilast foam achieved USD 45 million in 3Q-2024 revenue, driven by strong physician adoption. Leon Pharma's delgocitinib cream secured FDA Fast Track status in 2024, indicating regulatory acknowledgment of the need for steroid-sparing topicals. Over time, injectables backed by robust patient support programs should continue to gain allocation within the atopic dermatitis market.

Complete Report Scope:

• By Drug Class
  • Corticosteroids
  • Emollients / Moisturizers
  • IL-4, IL-13 & JAK (PDE4) Inhibitors
  • Calcineurin Inhibitors
  • Antibiotics & Antiseptics
  • Other Drug Classes
• By Route Of Administration
  • Topical
  • Oral
  • Injectable / Parenteral
• By Patient Age Group
  • Pediatric (0-17 Yrs)
  • Adult (18+ Yrs)
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies & Tele-Dermatology Platforms
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest Of Asia-Pacific
  • Middle-East And Africa
    • GCC
    • South Africa
    • Rest Of Middle East And Africa
  • South America
    • Brazil
    • Argentina
    • Rest Of South America

Geography Analysis

North America generated 41.30% of the 2025 revenue, bolstered by broad insurance coverage and early adoption of biologics. Medicare Part D reimburses dupilumab, and commercial plans usually approve biologics after one topical failure. Canada added tralokinumab to provincial formularies in mid-2024, diversifying options. Growth is moderating as penetration nears 40% of eligible moderate-to-severe patients, yet biosimilar entry after 2028 may reopen the pool by reducing cost barriers. The United States tele-dermatology infrastructure also amplifies biologic persistence, fostering steady refill cycles that stabilize the atopic dermatitis market.

Asia-Pacific is projected to grow at a 10.9% CAGR through 2031. China's December 2024 inclusion of tralokinumab in the reimbursement list and India's biosimilar dupilumab launch at a 40% discount underpin momentum. Japan subsidizes biologics for topical-refractory cases, though hospital-based administration slows access. South Korea signed data-linked risk-sharing agreements in 2025 that tie payment to real-world outcomes. Australia's benefits scheme listed lebrikizumab in 2025 as a second-line treatment. Environmental drivers, such as air pollution and dietary changes, continue to elevate the prevalence, reinforcing demand.

Europe shows moderate expansion. Germany reimburses biologics only after a documented failure of both topical steroids and phototherapy, which can extend lead times by up to 12 months. NICE criteria in the United Kingdom restrict prescribing to high-severity cases, suppressing volume. France and Italy focus on the biological use in hospital settings, which reduces convenience. South America remains nascent. Brazil's private insurers began covering dupilumab in 2024, but public plans did not adopt biologics, resulting in a two-tier market. Gulf states test value-based biologic contracts. Overall, regional divergences in payer policy drive uneven penetration; however, momentum in the Asia-Pacific region compensates for slower European ramp-ups, sustaining global expansion of the atopic dermatitis market.

1. Abbvie
2. Amgen
3. Arcutis Biotherapeutics
4. Bausch Health
5. Bristol-Myers Squibb
6. Cara Therapeutics
7. Dermavant Sciences Inc.
8. Eli Lilly and Company
9. Evelo Biosciences
10. Galderma
11. GlaxoSmithKline
12. Incyte Corp.
13. Kyowa Kirin Co. Ltd.
14. Leo Pharma
15. Novartis
16. Pfizer
17. Regeneron Pharmaceuticals
18. Sanofi

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support